Total Payments
$33,046
2024 Payments
$3,554
Companies
83
Transactions
529
Medicare Patients
9,384
Medicare Billing
$8.1M
Payment Breakdown by Category
Food & Beverage$8,681 (26.3%)
Research$8,422 (25.5%)
Other$6,812 (20.6%)
Consulting$6,120 (18.5%)
Education$1,653 (5.0%)
Travel$1,358 (4.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,681 | 451 | 26.3% |
| Unspecified | $8,422 | 10 | 25.5% |
| Consulting Fee | $6,120 | 3 | 18.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,500 | 2 | 13.6% |
| Long term medical supply or device loan | $2,312 | 25 | 7.0% |
| Education | $1,653 | 30 | 5.0% |
| Travel and Lodging | $1,358 | 8 | 4.1% |
Payments by Type
General
$24,624
519 transactions
Research
$8,422
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $5,314 | 67 | $0 (2024) |
| Medtronic USA, Inc. | $5,186 | 8 | $0 (2020) |
| Kite Pharma, Inc. | $3,883 | 17 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $3,392 | 16 | $0 (2021) |
| Eli Lilly and Company | $3,236 | 2 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,724 | 50 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $806.44 | 3 | $0 (2022) |
| Astellas Pharma US Inc | $583.01 | 20 | $0 (2024) |
| Seagen Inc. | $519.52 | 11 | $0 (2023) |
| Janssen Biotech, Inc. | $496.37 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,554 | 79 | Eli Lilly and Company ($1,065) |
| 2023 | $4,014 | 53 | Eli Lilly and Company ($2,171) |
| 2022 | $1,368 | 49 | Novartis Pharmaceuticals Corporation ($415.00) |
| 2021 | $2,705 | 56 | NOVARTIS PHARMACEUTICALS CORPORATION ($1,075) |
| 2020 | $5,609 | 45 | Kite Pharma, Inc. ($3,667) |
| 2019 | $4,989 | 96 | Medtronic USA, Inc. ($3,413) |
| 2018 | $7,629 | 100 | Puma Biotechnology, Inc. ($3,282) |
| 2017 | $3,179 | 51 | PFIZER INC. ($2,372) |
All Payment Transactions
529 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $25.50 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $24.80 | General |
| 12/13/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $18.77 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: Oncology | ||||||
| 11/26/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $34.02 | General |
| Category: DESMOID TUMORS | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $26.86 | General |
| Category: Oncology | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/13/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $24.07 | General |
| 11/12/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Eli Lilly and Company | — | — | In-kind items and services | $1,065.49 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 11/06/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: Bone Health | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug), DARZALEX | Food and Beverage | In-kind items and services | $40.02 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $25.27 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $29.51 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/19/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.63 | General |
| Category: Hematology | ||||||
| 09/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $2,171 | 1 |
| SCS Research | Medtronic USA, Inc. | $2,100 | 2 |
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $1,065 | 1 |
| OPuS ONE | Medtronic USA, Inc. | $700.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 41 | 2,315 | 76,875 | $8.4M | $2.0M |
| 2022 | 43 | 2,167 | 114,272 | $10.9M | $2.0M |
| 2021 | 46 | 2,431 | 94,453 | $9.1M | $2.0M |
| 2020 | 47 | 2,471 | 144,496 | $7.3M | $2.2M |
Total Patients
9,384
Total Services
430,096
Medicare Billing
$8.1M
Procedure Codes
177
All Medicare Procedures & Services
177 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 19,200 | $3.2M | $807,213 | 25.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 63 | 23,040 | $1.6M | $425,305 | 26.6% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 93 | 141 | $698,334 | $192,233 | 27.5% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 11 | 4,010 | $498,264 | $88,577 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 413 | 891 | $341,023 | $88,467 | 25.9% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 18 | 171 | $385,917 | $83,499 | 21.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 86 | 703 | $295,409 | $76,530 | 25.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 79 | 129 | $137,696 | $35,352 | 25.7% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 20 | 89 | $128,804 | $28,799 | 22.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 130 | 178 | $99,052 | $25,422 | 25.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 135 | 135 | $89,073 | $23,287 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 230 | 310 | $82,497 | $21,960 | 26.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 67 | 519 | $48,197 | $12,454 | 25.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 40 | 207 | $44,066 | $11,303 | 25.7% |
| J9070 | Cyclophosphamide, 100 mg | Office | 2023 | 12 | 619 | $46,538 | $9,659 | 20.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 44 | 177 | $35,246 | $9,543 | 27.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 55 | 57 | $29,497 | $8,062 | 27.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 46 | 343 | $30,574 | $7,808 | 25.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 11 | 15,300 | $239,572 | $6,101 | 2.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 57 | 473 | $24,603 | $5,795 | 23.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 55 | $19,410 | $5,337 | 27.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 100 | 420 | $19,451 | $4,887 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $18,417 | $4,733 | 25.7% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 15 | 93 | $16,505 | $4,199 | 25.4% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 11 | 1,171 | $39,485 | $3,121 | 7.9% |
About Dr. Ajithkumar Puthillath, MD
Dr. Ajithkumar Puthillath, MD is a Specialist healthcare provider based in Stockton, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/13/2009. The National Provider Identifier (NPI) number assigned to this provider is 1225275233.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ajithkumar Puthillath, MD has received a total of $33,046 in payments from pharmaceutical and medical device companies, with $3,554 received in 2024. These payments were reported across 529 transactions from 83 companies. The most common payment nature is "Food and Beverage" ($8,681).
As a Medicare-enrolled provider, Puthillath has provided services to 9,384 Medicare beneficiaries, totaling 430,096 services with total Medicare billing of $8.1M. Data is available for 4 years (2020–2023), covering 177 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Stockton, CA
- Active Since 01/13/2009
- Last Updated 07/31/2014
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1225275233
Products in Payments
- IBRANCE (Drug) $4,967
- Yescarta (Drug) $3,670
- Nerlynx (Drug) $3,319
- KISQALI (Drug) $2,210
- INTELLIS (Device) $2,100
- XPOVIO (Drug) $806.44
- OSTEOCOOL RF ABLATION (Device) $700.00
- Imbruvica (Drug) $365.55
- OPDIVO (Biological) $254.14
- KEYTRUDA (Biological) $238.79
- BRUKINSA (Drug) $221.45
- IMBRUVICA (Drug) $218.88
- VERZENIO (Drug) $197.83
- IMFINZI (Biological) $186.73
- XTANDI (Drug) $159.25
- JEVTANA (Drug) $150.00
- ZYTIGA (Drug) $143.48
- CINVANTI (Drug) $139.25
- Cabometyx (Drug) $136.73
- DARZALEX (Biological) $125.64
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Stockton
Gregory Bensch, M.d, M.D
Specialist — Payments: $1.8M
Specialist $1.8M
George Bensch, M.d, M.D
Specialist — Payments: $144,679
Specialist $144,679
Prasad Dighe, Md, MD
Specialist — Payments: $13,978
Specialist $13,978
Aminder Mehdi, Md, MD
Specialist — Payments: $10,156
Specialist $10,156
Josebelo Chong, Md, MD
Specialist — Payments: $7,732
Specialist $7,732
Dean Karnaze, Md, MD
Specialist — Payments: $5,510
Specialist $5,510